The milestone payment from Aventis, coupled with the upfront money from Novartis and royalties on Agenerase sales, will make this a very profitable quarter for Vertex. Perhaps the earnings "surpise" that will be announced sometime in August will drive the stock up. ASCO certainly did not. I admit to being disappointed that the company did not have any news on Incel worthy of a press release. For that matter, what is the status of the combination trial of VRTX IMPDH inhibitor along with interferon in hepatitis C? Perhaps it is the lack of significant news on the clinical front that makes this a quiet message board.